Axio BioPharma
Axio BioPharma is a Contract Development and Manufacturing Organization (CDMO) that leverages an AI-powered platform to revolutionize biopharmaceutical manufacturing, specifically monoclonal antibody (mAb) development. Their platform transforms raw sequence data into actionable insights, significantly reducing development timelines and costs by utilizing machine learning, experimental feedback, and bioprocessing expertise. Key features include intelligent amino acid profiling, self-learning feedback loops, in silico process optimization, and predictive process modeling. Axio BioPharma offers AI-enhanced services such as process development, discovery manufacturing, research-grade manufacturing, and GMP manufacturing through strategic partnerships. Their product, MKLP1 Pro™, consists of IgM and IgG antibodies for advanced biopharmaceutical research and diagnostics.
Axio BioPharma
Axio BioPharma is a Contract Development and Manufacturing Organization (CDMO) that leverages an AI-powered platform to revolutionize biopharmaceutical manufacturing, specifically monoclonal antibody (mAb) development. Their platform transforms raw sequence data into actionable insights, significantly reducing development timelines and costs by utilizing machine learning, experimental feedback, and bioprocessing expertise. Key features include intelligent amino acid profiling, self-learning feedback loops, in silico process optimization, and predictive process modeling. Axio BioPharma offers AI-enhanced services such as process development, discovery manufacturing, research-grade manufacturing, and GMP manufacturing through strategic partnerships. Their product, MKLP1 Pro™, consists of IgM and IgG antibodies for advanced biopharmaceutical research and diagnostics.